- Conditions
- Ulcerative Colitis
- Interventions
- vedolizumab, Placebo
- Drug · Other
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 895 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 102
- States / cities
- Birmingham, Alabama • Los Angeles, California • Montebello, California + 82 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 80
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Herpes Zoster, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
- Interventions
- Not listed
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 35 Years to 49 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Inflammatory Bowel Diseases
- Interventions
- Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine
- Biological
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Crohn Disease, Colitis, Ulcerative
- Interventions
- Ustekinumab, Other Biologic Therapies
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,536 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Crohn Disease, Ulcerative Colitis
- Interventions
- Not listed
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
- Interventions
- Not listed
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Crohn's Disease
- Interventions
- Vedolizumab, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 3
- States / cities
- Nashville, Tennessee • Southlake, Texas • Seattle, Washington
- Conditions
- Healthy Volunteers
- Interventions
- Vedolizumab SC
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Pouchitis
- Interventions
- Vedolizumab Placebo, Ciprofloxacin, Vedolizumab
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 10
- States / cities
- Chicago, Illinois • Evanston, Illinois • Minneapolis, Minnesota + 7 more
- Conditions
- Ulcerative Colitis
- Interventions
- Vedolizumab, Tofacitinib
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 37
- States / cities
- Dothan, Alabama • Sun City, Arizona • Los Angeles, California + 33 more
- Conditions
- Colitis, Ulcerative
- Interventions
- Vedolizumab IV
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 44
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • San Pablo, California + 40 more
- Conditions
- Crohn's Disease
- Interventions
- Vedolizumab SC 108 mg, Placebo, Vedolizumab IV 300 mg
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 644 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Hamden, Connecticut • Middletown, Connecticut + 27 more
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Herpes Zoster
- Interventions
- Shingrix
- Biological
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Crohn's Disease
- Interventions
- Vedolizumab
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 22
- States / cities
- La Jolla, California • Hamden, Connecticut • Gainesville, Florida + 19 more
- Conditions
- Colitis, Ulcerative, Crohn's Disease
- Interventions
- Vedolizumab
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Chicago, Illinois • Urbana, Illinois + 4 more
- Conditions
- Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis, Vitamin D Deficiency
- Interventions
- vitamin D3
- Dietary Supplement
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 5 Years to 25 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Colitis, Ulcerative
- Interventions
- Vedolizumab 300 mg IV, Placebo IV, Vedolizumab 108 mg SC, Placebo SC
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 28
- States / cities
- Little Rock, Arkansas • Wheat Ridge, Colorado • Middletown, Connecticut + 25 more
- Conditions
- Ulcerative Colitis, Crohn's Disease
- Interventions
- Vedolizumab IV, Vedolizumab SC
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Loma Linda, California • Orange, California + 10 more
- Conditions
- Crohn's Disease
- Interventions
- Vedolizumab (VDZ), Ustekinumab (UST), Risankizumab (RISA), Guselkumab (GUS), Mirikizumab (MIR)
- Drug
- Lead sponsor
- Alimentiv Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 11
- States / cities
- Sun City, Arizona • Evanston, Illinois • Iowa City, Iowa + 8 more
- Conditions
- Crohn's Disease (CD)
- Interventions
- Vedolizumab IV
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Diego, California + 19 more
- Conditions
- Ulcerative Colitis, Crohn's Disease
- Interventions
- Vedolizumab
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 6 more
- Conditions
- Crohn's Disease
- Interventions
- Vedolizumab, Adalimumab, Ustekinumab
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 41
- States / cities
- Dothan, Alabama • Sun City, Arizona • La Jolla, California + 37 more
- Conditions
- Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Melanoma
- Interventions
- Infliximab, Vedolizumab
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HIV
- Interventions
- Entyvio (Vedolizumab)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland